• The European project funded by the Interreg SUDOE programme celebrates the 18th of April an event to present its main results to the biohealth sector
• It will be showcased an innovative solution developed to repair the damaged tissue of the heart of cardiac patients
• There is the opportunity to see the encounter face-to-face and through streaming. It will approach the role of regenerative medicine in CDV as well

The CARDIOPATCH project, co-financed by the Interreg SUDOE Programme through the European Regional Development Fund (ERDF), comes to an end after three years of research to develop a new advanced therapy model for myocardial infarction patients.

The partners of the project will present the results of this work in an event in Pamplona (Spain), in the Assembly Hall of Cima Universidad de Navarra, the next 18th of April.

It is aimed for biohealth and 3D printing professionals and there is the opportunity to see the encounter face-to-face and through streaming. The entry is totally free and in order to assist it is needed to complete this form.   

Besides, the people not able to be in Pamplona have the chance to follow it live through the YouTube channel of Clínica Universidad de Navarra.   

Full programme: Results of the CARDIOPATCH European network

The Dr. Felipe Prósper, director of the Cell Therapy Area at Clínica Universidad de Navarra and coordinator of the CARDIOPATCH project, will be in charge of presiding the opening of the event at 9:30 AM (CEST). 

Then, the results of the initiative will be showcased as well as the advances made by the CARDIOPATCH network in the new advanced therapy for the treatment of myocardial infarction based on regenerative medicine and 3D printing.

• 09:45-10:00 - Development of a collagen patch as regenerative therapy for myocardial infarction (Dr. Beatriz Pelacho, scientific coordinator of CARDIOPATCH and researcher of Cima Universidad de Navarra).
• 10:00-10:15 - Materials for biomedical applications (Mr. Jesús Izco, Bioproducts Diversification Manager of the associate partner Viscofan).
• 10:15-10:30 - Cellular production upscaling technologies for clinic and technology
• translation (Dr. Margarida Serra, researcher from the Instituto de Biologia Experimental e Tecnológica, iBET, partner of the project).
• 10:30-10:45 - Presentation of the device for the patch culture and transport (Ms. Uzuri Urtaza and Mr. Mikel Garmendia, researchers from the partner Leartiker).
• 10:45-11:00 - Presentation of the device for the heart patch implantation using minimally invasive techniques (Ms. Uzuri Urtaza and Mr. Mikel Garmendia). 

After these interventions, it will be analyzed the potential of regenerative medicine in the treatment of cardiovascular diseases. 

The Dr. Manuel García de Yébenes Castro, from the Cardiology Department at Clínica Universidad de Navarra, will offer a presentation at 11:30 that will be followed by a roundtable discussion moderated by Dr. Felipe Prósper and with the participation of the entities Cardioalianza, Clínica Universidad de Navarra and Viscofan. 

The event will be closed with a presentation of the main services of the platform developed by the CARDIOPATCH network as well as the impact achieved during the lifetime of the project.  

Consortium final meeting

The 17th of April, a day before the event, the partners of the project’s consortium will gather also in Pamplona to exchange and analyse internally the results obtained. 

To be concrete, the consortium has focused on the design and validation of an innovative patch based on regenerative medicine and 3D printing technologies capable of offering a  definitive solution for patients with myocardial infarction through the regeneration of the damaged tissue of the heart. 

Together with the patch, the project has also developed a device for its implantation at the heart with minimally invasive techniques for the patient. 

Led by Clínica Universidad de Navarra, the initiative includes partners from Spain, France and Portugal: Cima Universidad de Navarra, through the Foundation for Applied Medical Research, Leartiker Technology Centre, la Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.